VS-01
Phase 2- Indications
- Acute-on-chronic liver failure, Urea cycle disorder
Company intelligence / Profile preview
Versantis AG
Zurich, Zurich, Switzerlandversantis.net ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
VS-01 was shown to be safe and well tolerated in a Phase 1b study with positive efficacy outcomes, and was ready to start Phase 2a clinical investigations as of the last update[2]
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Liposome-based therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Versantis AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Versantis AG.